VRIO Analysis of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG

Posted by Zachary Edwards on Mar-22-2018

The VRIO Analysis of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.

Valuable

• The DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG VRIO Analysis shows that the financial resources of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG are highly valuable as these help in investing into external opportunities that arise. These also help DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG in combating external threats.
• According to the VRIO Analysis of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
• The DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG VRIO Analysis shows that DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG's products.
• According to the VRIO Analysis of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG. These patents also provide DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG with licensing revenue when it licenses these patents out to other manufacturers.
• The DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG VRIO Analysis shows that DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG. It also ensures that promotion activities translate into sales as the products are easily available.
• According to the VRIO Analysis of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
• The DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG VRIO Analysis shows that the research and development at DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG. It is recommended that the research and development teams are improved, and costs are cut for these.

Rare

• The financial resources of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG are found to be rare according to the VRIO Analysis of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG. Strong financial resources are only possessed by a few companies in the industry.
• The local food products are found to be not rare as identified by DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG and inhibit competitive advantage. This means that the local food products result in competitive parity for DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG. As this resource is valuable, DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG can still make use of this resource.
• The employees of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG are a rare resource as identified by the VRIO Analysis of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
• The patents of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG are a rare resource as identified by the DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG to use them without interference from the competition.
• The distribution network of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG is a rare resource as identified by the VRIO Analysis of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG. These are also possessed by very few firms in the industry.

Imitable

• The financial resources of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG are costly to imitate as identified by the DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
• The local food products are not that costly to imitate as identified by the VRIO Analysis of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG provide it with a temporary competitive advantage that competitors can too acquire in the long run.
• The employees of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG are also not costly to imitate as identified by the DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
• The patents of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG are very difficult to imitate as identified by the VRIO Analysis of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
• The distribution network of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG is also very costly to imitate by competition as identified by the DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG VRIO Analysis. This has been developed over the years gradually by DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.

Organisation

• The financial resources of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG are organised to capture value as identified by the VRIO Analysis of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG.
• The Patents of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG are not well organised as identified by the DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG starts selling patented products before the patents expire.
• The distribution network of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG is organised as identified by the VRIO Analysis of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG. DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG.

From the VRIO Analysis of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of DELTA PHARMACEUTICALS WHY WON T SALES AND MARKETING GET ALONG is a competitive disadvantage. Research and Development is also a competitive disadvantage.